MBX Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

MBX Biosciences şirketinin toplam hissedar öz sermayesi $409.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $435.9M ve $26.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$418.58m
Eşitlik	US$409.54m
Toplam yükümlülükler	US$26.37m
Toplam varlıklar	US$435.91m

Son finansal sağlık güncellemeleri

Analiz Makalesi • Jun 28

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Mar 13

We're Not Very Worried About MBX Biosciences' (NASDAQ:MBX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Recent updates

Seeking Alpha • Jul 06

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

Summary I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks. MBXX's obesity pipeline offers asymmetric upside, while $440M cash extends runway into 2029, mitigating near-term financing risk. Canvuparatide's phase 3 readout comes with risk, similar to recent Eneboparatide failing phase 3 trial (although their ph2 was positive), so we see MBX as a speculative buy. Read the full article on Seeking Alpha

Analiz Makalesi • Jun 17

MBX Biosciences (MBX) Stock Looks Fully Valued After New Phase 2 Data

MBX Biosciences (MBX) has drawn fresh attention after publishing full Phase 2 Avail and one-year open-label data for its lead candidate canvuparatide in chronic hypoparathyroidism, alongside confirming plans for a pivotal Phase 3 trial. See our latest analysis for MBX Biosciences. Against this backdrop, MBX Biosciences stock has seen strong momentum, with a 7 day share price return of 29.36% and a 90 day share price return of 41.01%, while the 1 year total shareholder return is very large at...

Analiz Makalesi • Jun 28

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Mar 13

We're Not Very Worried About MBX Biosciences' (NASDAQ:MBX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Seeking Alpha • Nov 14

MBX Biosciences: Decent Potential For Lead Indication, But Need More Data

Summary MBX Biosciences, a recent IPO, develops precision peptide therapies for endocrine and metabolic disorders, with lead asset MBX 2109 in phase 2 for Hypoparathyroidism. MBX 2109, a once-weekly PTH replacement therapy, shows promising phase 1 results with stable drug concentration and potential to improve patient compliance over daily treatments. Financially, MBX has a market cap of $784mn and a cash runway of 12-14 quarters, sufficient to reach phase 2 trial data by Q3 2025. Despite promising prospects, I will wait for phase 2 trial data and pricing information before considering a position, while monitoring Yorvipath's market performance. Read the full article on Seeking Alpha

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MBX 'nin kısa vadeli varlıkları ( $427.9M ) kısa vadeli yükümlülüklerini ( $23.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: MBX şirketinin kısa vadeli varlıkları ( $427.9M ) uzun vadeli yükümlülüklerini ( $2.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MBX borçsuzdur.

Borcun Azaltılması: MBX son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MBX şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: MBX serbest nakit akışı her yıl % 34.7 1.9 yıl yetecek nakit akışına sahip olacaktır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/08/09 14:16
Gün Sonu Hisse Fiyatı	2026/08/07 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

MBX Biosciences, Inc. 14 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Eliana Merle	Barclays
Jonathan Wolleben	Citizens JMP Securities, LLC
Corinne Johnson	Goldman Sachs

MBX Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

We're Not Very Worried About MBX Biosciences' (NASDAQ:MBX) Cash Burn Rate

Recent updates

MBX Biosciences Advances Canvuparatide and Expands Obesity Pipeline With New Clinical Data

Price target increased by 7.1% to US$74.00

MBX Biosciences, Inc. Announces CEO Changes, Effective July 13, 2026

MBX Biosciences Names Steve Hoerter CEO and John Smither CFO in Leadership Transition

Imapextide Wins FDA Orphan Drug Status as MBX Biosciences Advances in Rare Disease Trials

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell Microcap Value Benchmark Index

MBX Biosciences (MBX) Stock Looks Fully Valued After New Phase 2 Data

MBX Biosciences Shares Fall Despite Encouraging One-Year Canvuparatide Study Results

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential PTH Replacement Therapy In Chronic Hypoparathyroidism

Price target increased by 10% to US$69.09

Chief Medical Officer notifies of intention to sell stock

MBX Biosciences Prepares for Phase 3 Canvuparatide Trial With Strong Cash Position

MBX Biosciences, Inc., Annual General Meeting, Jun 04, 2026

Price target increased by 7.8% to US$65.89

New major risk - Revenue and earnings growth

MBX Biosciences, Inc. Appoints Karen Basbaum As Chief Business Officer

MBX Biosciences, Inc. Announces Board and Committee Changes

Price target increased by 9.2% to US$64.43

Mbx Biosciences, Inc. Announces Changes to Its Board, Effective from October 31, 2025

MBX Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

CEO, President & Director exercised options to buy US$3.6m worth of stock.

Insider recently bought US$265k worth of stock

New major risk - Shareholder dilution

MBX Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $199.94499 million.

MBX Biosciences, Inc. Plans to Initiate A Phase 3 Clinical Trial of Once-Weekly Canvuparatide in 2026

New major risk - Share price stability

Price target increased by 32% to US$49.43

MBX Biosciences, Inc. Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responsonder Rate at 12 Weeks;79% Responder Rate at 6 Months in Open-Label Extension

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

New major risk - Revenue and earnings growth

MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell Small Cap Comp Growth Index

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

MBX Biosciences, Inc Appoints Andreas Moraitis as Senior Vice President of Clinical Development

MBX Biosciences, Inc. Announces IND Submission of MBX 4291, its Long-Acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

MBX Biosciences, Inc. to Present At the American Diabetes Association 85Th Scientific Sessions

MBX Biosciences, Inc. Announces Departure of Carl L. Gordon from the Company's Board of Directors, Effective June 5, 2025

MBX Biosciences, Inc., Annual General Meeting, Jun 05, 2025

MBX Biosciences, Inc. Announces the Appointment of Steve Hoerter as an Independent Director, Effective April 7, 2025

We're Not Very Worried About MBX Biosciences' (NASDAQ:MBX) Cash Burn Rate

MBX Biosciences, Inc. Announces Management Appointments

MBX Biosciences, Inc. Completes Enrollment in Phase 2 Avail™? Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

CEO, President & Director recently bought US$535k worth of stock

MBX Biosciences, Inc. Announces Positive Phase 1 Topline Data for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (PBH)

High number of new directors

MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism

Mbx Biosciences, Inc. Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia

MBX Biosciences: Decent Potential For Lead Indication, But Need More Data

MBX Biosciences, Inc. Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

MBX Biosciences, Inc. has completed an IPO in the amount of $163.2 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları